The price isn’t the real price, even in overseas markets. And if the US government is serious about drug price reductions, should it return to the idea of direct…
Big pharma’s freezes have stopped drug price inflation in its tracks, but the temptation to make more hikes could return post-election.
Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Biopharma might be getting the pricing controls that it tried to stop.
Private price negotiation is a hallmark of the US health care system – banning rebates does not make that any less true.
Drug price inflation has slowed to crawl, but political pressure can only keep a lid on costs for so long.
Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?
A recent US push to end drug rebates might improve transparency, but will do nothing to address the root cause of rising drug costs.
Biopharma companies have benefited from public funding for their early research, so do they have the right to charge high prices for these projects?